1. Home
  2. RXO vs IMCR Comparison

RXO vs IMCR Comparison

Compare RXO & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RXO Inc.

RXO

RXO Inc.

HOLD

Current Price

$14.43

Market Cap

2.2B

Sector

N/A

ML Signal

HOLD

Logo Immunocore Holdings plc

IMCR

Immunocore Holdings plc

HOLD

Current Price

$32.75

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RXO
IMCR
Founded
2022
2008
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.8B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
RXO
IMCR
Price
$14.43
$32.75
Analyst Decision
Hold
Buy
Analyst Count
15
10
Target Price
$16.25
$65.33
AVG Volume (30 Days)
2.0M
284.1K
Earning Date
02-04-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,940,000,000.00
$379,590,000.00
Revenue This Year
$28.02
$32.28
Revenue Next Year
$3.31
$10.66
P/E Ratio
N/A
N/A
Revenue Growth
53.85
28.11
52 Week Low
$10.43
$23.15
52 Week High
$26.92
$40.72

Technical Indicators

Market Signals
Indicator
RXO
IMCR
Relative Strength Index (RSI) 58.96 33.89
Support Level $12.45 $34.00
Resistance Level $12.87 $34.97
Average True Range (ATR) 0.62 1.40
MACD 0.04 -0.43
Stochastic Oscillator 80.60 4.95

Price Performance

Historical Comparison
RXO
IMCR

About RXO RXO Inc.

RXO Inc is a brokered transportation platform defined by cutting-edge technology and a nimble, asset-light business model, with the component being core truck brokerage business. Its operations also include three asset-light, brokered transportation services, all of which complement its truck brokerage business: managed transportation, last mile and freight forwarding. The company operates into one reportable segment. The operates within the transportation industry and in the same geography North America.

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Share on Social Networks: